Sucampo Pharma Llc patent expiration

1. Amitiza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5284858 SUCAMPO PHARMA LLC Prostaglandins E and anti ulcers containing same
Jul, 2014

(10 years ago)

US8114890 SUCAMPO PHARMA LLC Anti-constipation composition
Sep, 2020

(3 years ago)

US8071613 SUCAMPO PHARMA LLC Anti-constipation composition
Sep, 2020

(3 years ago)

US6414016 SUCAMPO PHARMA LLC Anti-constipation composition
Sep, 2020

(3 years ago)

US7417067 SUCAMPO PHARMA LLC Composition and method for stabilizing the same
Oct, 2020

(3 years ago)

US8097649 SUCAMPO PHARMA LLC Composition and method for stabilizing the same
Oct, 2020

(3 years ago)

US6583174 SUCAMPO PHARMA LLC Composition and method for stabilizing the same
Oct, 2020

(3 years ago)

US8088934 SUCAMPO PHARMA LLC Composition and method for stabilizing the same
May, 2021

(3 years ago)

US7064148 SUCAMPO PHARMA LLC Chloride channel opener
Aug, 2022

(1 year, 10 months ago)

US8389542 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation
Nov, 2022

(1 year, 8 months ago)

US8097653 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation
Nov, 2022

(1 year, 8 months ago)

US6982283 SUCAMPO PHARMA LLC Method for treating drug-induced constipation
Dec, 2022

(1 year, 7 months ago)

US7795312 SUCAMPO PHARMA LLC Method for treating abdominal discomfort
Sep, 2024

(a month from now)

US8748481 SUCAMPO PHARMA LLC Method for treating gastrointestinal disorder
Sep, 2025

(1 year, 1 month from now)

US8779187 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(2 years from now)

US8338639 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(2 years from now)

US8026393 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Oct, 2027

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-670) Apr 19, 2016
M(M-225) Apr 26, 2021

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 29 April, 2008

Treatment: Method for relieving or treating constipation in a human constipated patient; Method of relieving or preventing constipation in a human constipated patient; Method for treating constipation by opening...

Dosage: CAPSULE

How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage

AMITIZA family patents

Family Patents

2. Rescula patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5221763 SUCAMPO PHARMA LLC Prostaglandins of the F series
Jul, 2012

(12 years ago)

US6770675 SUCAMPO PHARMA LLC Compositions and methods for reducing ocular hypertension
Nov, 2018

(5 years ago)

US6458836 SUCAMPO PHARMA LLC Treatment of ocular hypertension and glaucoma
Jul, 2021

(3 years ago)




Drugs and Companies using UNOPROSTONE ISOPROPYL ingredient

Market Authorisation Date: 03 August, 2000

Treatment: Method of reducing ocular hypertension; Method of treating ocular hypertension

Dosage: SOLUTION/DROPS

How can I launch a generic of RESCULA before it's drug patent expiration?
More Information on Dosage

RESCULA family patents

Family Patents